ALN-2232 (ACVR1C) Overview

An Investigational RNAi Therapeutic

Disease State(s) Under Investigation	Obesity & weight management[1]
MoA	Designed to target production of activin A receptor type 1C (ACVR1C)[1]
Route of Administration	Subcutaneous[1]

Clinical Trials Overview

Phase 1	Treatment Arms	Primary Endpoint
Recruiting		
Safety, Tolerability, Efficacy, PK, and PD of **ALN-2232** Adult Patients With Obesity[1]	ALN-2232; placebo	Safety (frequency and severity of AEs)

The safety and efficacy of ALN-2232 (ACVR1C) has not been established by any health authority.

AE, adverse event; ACVR1C, activin A receptor, type IC; MoA, mechanism of action; PD, pharmacodynamics; PK, pharmacokinetics; RNA, ribonucleic acid; RNAi, RNA interference. 1. ClinicalTrials.gov. 2026. https://clinicaltrials.gov/study/NCT07463846 (Accessed May 4, 2026).

Alnylam